Drug Trial Radar · NCT06621654
Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
160
Actual
Start
Nov 15, 2024
Primary completion
Oct 2026
Study completion Oct 2026
Sponsor
- Lead sponsor
- CanSino Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 months, up to 59 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of age groups, from the oldest to the youngest, and the initial safety assessment will be conducted on the 8th day after the first dose of vaccination for each age group, and the next group will be enrolled only after the safety is confirmed.
Conditions
- Haemophilus Influenzae Type B Infection
Interventions
Lyophilized Haemophilus Influenzae Type b Conjugate VaccineBiological
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
Lyophilized Haemophilus Influenzae Type b Conjugate VaccineBiological
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
Haemophilus Influenzae Type b Conjugate VaccineBiological
1 dose (0.5ml) of vaccine on day 0, Intramuscular injection
Lyophilized Haemophilus Influenzae Type b Conjugate VaccineBiological
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
Haemophilus Influenzae Type b Conjugate VaccineBiological
3 doses (0.5ml per dose) at day 0, 1 month, and 18 months of age, Intramuscular injection
Lyophilized Haemophilus Influenzae Type b Conjugate VaccineBiological
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age, Intramuscular injection
Haemophilus Influenzae Type b Conjugate VaccineBiological
4 doses (0.5ml per dose) at day 0, 2, 4 month, and 18 months of age. Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse reactions in all subjectsTime frame: Within 30 days of each dose of vaccine
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiulongpo District Center for Disease Control and Prevention
Chongqing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.